Gabapentin
Product Images NDC 68788-9509

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 68788-9509). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Preferred Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Gabapentin Capsules, Usp 400mg

Gabapentin Capsules, USP 400 mg label from Preferred Pharmaceuticals, Inc. The label states it is generic for Neurontin and manufactured by Ascend Laboratories, LLC. Storage instructions are included along with dosage instructions in English and Spanish. The capsule is described as orange and imprinted with 214.*

FDA Label Image

Gabapentin-equation (Gabapentin Equation)

An equation formula calculating creatinine clearance (CLCr) based on age in years, weight in kilograms, serum creatinine in mg/dL, and a factor of 0.85 for female patients. This diagram illustrates the mathematical relationship for renal function assessment.*

FDA Label Image

Gabapentin Fig1

A line graph showing the mean pain score over an 8-week period comparing placebo and Gabapentin at 3600 mg/day. The x-axis represents weeks, and the y-axis shows mean pain score. The graph indicates a 4-week dose titration period followed by a 4-week fixed dose period, with Gabapentin showing a decrease in mean pain score over time compared to placebo.*

FDA Label Image

Gabapentin Fig2

A line graph depicting mean pain scores over seven weeks comparing Placebo, Gabapentin 1800 mg/day, and Gabapentin 2400 mg/day. The study includes a 3-week dose titration period followed by a 4-week fixed dose period. Gabapentin groups show a decrease in mean pain scores compared to placebo over time.*

FDA Label Image

Gabapentin Fig3

A bar chart illustrating the proportion of responders (patients with at least 50% reduction in pain score) at the endpoint of two controlled PHN studies for Gabapentin. Study 1 compares placebo (PBO) at 12% and Gabapentin 3600 mg at 29%. Study 2 compares placebo at 14%, Gabapentin 1800 mg at 32%, and Gabapentin 2400 mg at 34%. Statistical significance levels are indicated for comparisons.*

FDA Label Image

Gabapentin-fig4 (Gabapentin Fig4)

A scatter plot graph displaying percentage difference on the vertical axis versus daily dose in milligrams on the horizontal axis for three studies labeled a, b, and c. The graph shows data points for daily doses of approximately 600, 900, 1200, and 1800 mg, with each study represented by different colored squares (black for study a, gray for study b, and white for study c). Letters 'a', 'b', and 'c' appear near data points to distinguish the studies.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.